Charles River Laboratories International, Inc. (CRL) Earnings Call Transcripts
Charles River Laboratories International, Inc.'s Latest Earnings Call - September 24, 2026
In the third quarter of fiscal year 2026, Charles River Laboratories (CRL:US) reported a revenue of $1.1 billion, slightly above the $1.05 billion consensus estimate, reflecting a year-over-year growth of 6%. The company also achieved an adjusted EPS of $1.50, beating expectations by $0.10. Management maintained its long-term growth guidance, projecting a compound annual growth rate (CAGR) of 5% to 7% through 2030, while targeting an operating margin expansion to approximately 24%. The focus on modernization and strategic investments in bioanalysis and AI technologies were highlighted as key growth drivers moving forward.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $1.1B (beat) |
| EPS | $1.50 (beat) |
| Operating Margin Target | 24% (inline) |
| CAGR Revenue Growth | 5% to 7% (inline) |
| Cumulative Savings from Modernization | $300M (inline) |
| FDA-Approved Drugs Supported | 80% (positive) |
Guidance from management
Management maintained its long-term revenue growth guidance of 5% to 7% CAGR through 2030 and targeted an operating margin expansion to approximately 24%. They also expect to achieve $300 million in cumulative savings from modernization efforts by 2030.
What management said
Great. Thank you, Mark. As Mark said, we'll now start our Q&A session. If you could just state your name and firm for everybody on the webcast, that would be appreciated and wait until you have 1 of the 2 mics before asking a question. Thank you.
I would just say that the way we've sequenced the savings is pretty even and linear throughout the plan. A lot of the low-hanging fruit around the previous cost savings efforts that have taken place is no longer with us. So we're dealing with now implementing AI, automation, investments required to generate the savings. So it will take us a little bit longer to get to some of these savings, but I would just say, thin...
What analysts pressed on
Analysts expressed concerns about geopolitical risks, particularly regarding supply chain issues in China and the potential impact on nonhuman primate sourcing. There were also questions about the pace of margin expansion and the sustainability of recent revenue growth rates.
Main topics on the call
- Revenue Growth and Guidance — Charles River reported Q3 revenue of $1.1 billion, exceeding the $1.05 billion estimate and reflecting a 6% YoY increase. Management reiterated its long-term revenue growth guidance of 5% to 7% CAGR through 2030, signali...
- Margin Expansion Initiatives — Management indicated a target to expand operating margins to approximately 24% by 2030, driven by cost-saving initiatives and operational efficiencies. CEO Birgit Girshick stated, "We are modernizing, we're optimizing, w...
- Bioanalysis as a Growth Driver — The bioanalysis segment is expected to be a significant growth area, with plans to expand capabilities into clinical stages. Management noted, "We believe bioanalysis will improve the business mix and increase our share ...
- AI and Digital Transformation — Charles River is leveraging AI and digital tools to enhance operational efficiency and client experience. CFO Glenn Coleman mentioned that the company is targeting $300 million in cumulative savings from modernization ef...
Read the full Charles River Laboratories International, Inc. transcript (September 24, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. (CRL) is a publicly listed company in the Life Sciences Tools and Services industry, within the Health Care sector. It trades on NYSE and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 119 calls on record spanning January 14, 2020 to September 24, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 119 Charles River Laboratories International, Inc. earnings call transcripts on record, spanning January 14, 2020 to September 24, 2026. Based on this history, Charles River Laboratories International, Inc. reports quarterly. The most recent call on file is dated September 24, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- CRL
- Exchange
- NYSE
- Country
- US
- Sector
- Health Care
- Industry
- Life Sciences Tools and Services
- Calls on record
- 119
- First call
- January 14, 2020
- Most recent
- September 24, 2026
- Reporting cadence
- quarterly